Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Lung cancer in 2013

Refining standard practice and admitting uncertainty

Nature Reviews Clinical Oncology volume 11, pages 69–70 (2014)Cite this article

Subjects

In 2013, the treatment of several NSCLC subtypes was refined. PROFILE-1007 and LUX-Lung 3 confirmed that targeted therapy was superior to chemotherapy, whereas NCIC BR19 and PointBreak failed to show superiority of adjuvant gefitinib and combined maintenance therapy, respectively. These studies reinforced some practices and discouraged others, underscoring the need for new prospective studies.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).

    Article  CAS  Google Scholar 

  2. Kim, D. W. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 30 (Suppl. 15), a7533 (2012).

    Google Scholar 

  3. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).

    Article  CAS  Google Scholar 

  4. Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327–3334 (2013).

    Article  CAS  Google Scholar 

  5. Yang, J. C. et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3342–3350 (2013).

    Article  CAS  Google Scholar 

  6. Yang, J. C. et al. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: findings from three prospective trials of afatinib in EGFR mutation-positive lung cancer [abstract]. World Conference on Lung Cancer, 1114, 003.05 (Sidney, Australia, 2013).

    Google Scholar 

  7. Goss, G. D. et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J. Clin. Oncol. 31, 3320–3326 (2013).

    Article  CAS  Google Scholar 

  8. Kelly, K. et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450–2456 (2008).

    Article  CAS  Google Scholar 

  9. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005).

    Article  CAS  Google Scholar 

  10. Patel, J. D. et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIb or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 31, 4349–4357 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lombardi Comprehensive Cancer Center, Georgetown University, 3800 Reservoir Road NW, 20007, Washington, DC, USA

    Stephen V. Liu & Giuseppe Giaccone

Authors
  1. Stephen V. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Giaccone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Giaccone.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, S., Giaccone, G. Refining standard practice and admitting uncertainty. Nat Rev Clin Oncol 11, 69–70 (2014). https://doi.org/10.1038/nrclinonc.2013.251

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.251

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing